Plays an anti-inflammatory role in the mammalian intestine. The supernatant of this bacteria, or 2 purified fractions containing peptides derived from this protein, exerts inhibitory effects on IL1-beta-induced IL-8 secretion in intestinal epithelial CaCO-2 cells (PubMed:18936492, PubMed:26045134). Mice fed this bacterium suffer less severe symptoms in 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced colitis (PubMed:18936492). Expression in human epithelial cell lines (HEK293T, HT29) shows a decrease in activation of NF-kappa-B induced by Carma-1 (CARD11) or lipopolysaccharide. The decrease occurs in a MAM-dose dependent manner. Also inhibits activation induced by IKBKB in HEK293T cells. Expression in cell lines has no effect on the STAT3 pathway. L.lactis expressing the protein offers a protective effect to mice in dinitrobenzene sulfonic acid (DNBS) and dextran sodium sulfate (DSS)-induced colitis (PubMed:26045134, PubMed:28203226). It may play a role in maintaining the intestinal barrier, which is important in diabetes mellitus (Probable). Detected in cell supernatants as a mixture of peptides corresponding to residues 49-68; 50-68; 51-68; 52-68; 53-68; 69-111 and 112-135. When transfected in human cells surrounds the nucleus and colocalizes with IKBKB. Transcribed in the gut of mice with diabetes mellitus (db/db mice). Crohn disease is an inflammatory bowel disease. This commensal, butyrate-producing bacterium, isolated from a human fecal sample, is reduced in some patients suffering from Crohn disease (PubMed:18936492). In a mouse model of diabetes mellitus there is a significantly reduced population of Faecalibacterium (PubMed:31503404).